Nasello, M.; Zancan, V.; Rinaldi, V.; Marrone, A.; Reniè, R.; Diamant, S.; Marconi, M.; Le Mura, L.; Salvetti, M.; Buscarinu, M.C.;
et al. Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience. Int. J. Mol. Sci. 2024, 25, 5353.
https://doi.org/10.3390/ijms25105353
AMA Style
Nasello M, Zancan V, Rinaldi V, Marrone A, Reniè R, Diamant S, Marconi M, Le Mura L, Salvetti M, Buscarinu MC,
et al. Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience. International Journal of Molecular Sciences. 2024; 25(10):5353.
https://doi.org/10.3390/ijms25105353
Chicago/Turabian Style
Nasello, Martina, Valeria Zancan, Virginia Rinaldi, Antonio Marrone, Roberta Reniè, Selene Diamant, Martina Marconi, Lorenzo Le Mura, Marco Salvetti, Maria Chiara Buscarinu,
and et al. 2024. "Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience" International Journal of Molecular Sciences 25, no. 10: 5353.
https://doi.org/10.3390/ijms25105353
APA Style
Nasello, M., Zancan, V., Rinaldi, V., Marrone, A., Reniè, R., Diamant, S., Marconi, M., Le Mura, L., Salvetti, M., Buscarinu, M. C., & Bellucci, G.
(2024). Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience. International Journal of Molecular Sciences, 25(10), 5353.
https://doi.org/10.3390/ijms25105353
